Okayama University research: Enzyme target for slowing bladder cancer invasion

(Okayama, 09 January) Researchers at Okayama University have uncovered a potential new therapeutic target for invasive bladder cancer. The GTP hydrolysing enzyme (GTPase), called Dynamin2, facilitates the rapid invasion of cancer into surrounding tissues; inhibiting its activity could limit the progression of bladder cancer.

Bladder cancer is one of the most common forms of urological cancer, and removal of the bladder remains the primary method for treating the condition. However, the surgery impacts heavily on patients’ quality of life and places considerable burden on healthcare services to care for those in recovery. Alternative treatment methods are sought to reduce the need for such drastic surgery.

Many cancers, including bladder cancer, progress via the formation of ‘invadopodia’ – protrusions made from bundles of F-actin that promote cell invasion by degrading the extracellular matrix of healthy cells. A family of GTPase known as Dynamin have been implicated in cancer progression and invadopodia, but the precise mechanisms involved are unclear.

With this in mind, Tetsuya Takeda and co-workers at Okayama University investigated the role of three types of Dynamin (1, 2, & 3) in invasive bladder cancer. They found that all the three Dynamin isoforms were expressed in bladder cancer cell lines, but that only Dynamin2 localized to the invadopodia.

Further examination showed that the proline/arginine-rich domain of Dynamin2 is vital to the correct formation of invadopodia. Takeda’s team found that Dynamin2 interacts with cortactin – a protein that can trigger the rearrangement of F-actin filaments – and that these interactions are crucial for the stable formation of invadopodia. When the researchers inhibited Dynamin2 in cancer cell lines, they observed severe defects in invadopodia formation and suppression of cancer cell invasive activity.

While further investigations are needed to clarify the mechanisms involved in invadopodia formation, these results indicate that Dynamin2 may provide a valuable therapeutic target to reduce the growth and invasiveness of bladder cancer.

Background

Cancer cell invasion

Cancer cells use invadopodia – protrusions on the cell membrane created by bundles of F-actin (linear polymer microfilaments) – to degrade surrounding tissues (invasion). Invadopodia are also implicated in a cancer’s ability to metastasize. Scientists believe that, if
they can work out how to prevent invadopodia formation in different cancers, the progression and invasiveness of the cancer could be better contained and more easily treated, thus reducing the need for surgery and more aggressive treatments.

The Dynamin family proteins play a key role in the absorption of hormones and proteins by healthy cells. However, Dynamin2 has also been implicated in cancer cell migration and metastatic invasion because of its ability to stabilize actin-based structures. This led Tetsuya Takeda and his team to hypothesize that Dynamin2 may be involved in the formation of F-actin-based invadopodia. Their results show that Dynamin2 is a vital component of correct invadopodia formation in invasive bladder cancer. More precisely, interactions between Dynamin2 and the cortactin protein create more stable F-actin structures, encouraging invadopodia growth.

**Implications of the current study**

The discovery that Dynamin2 plays a crucial role in the correct formation of invadopodia could inform future treatments for bladder cancer. Takeda’s team successfully inhibited Dynamin2 activity in cancer cell lines, leading to defective invadopodia and the suppression of the cancer’s invasive properties. Following further investigations, the same principle could be carried forward to create a new bladder cancer therapy that targets Dynamin2.

**Figure.** Graphical abstract of Dynamin2 function at the invadopodia. Dynamin2 and cortactin forms a “ring” shaped complex required for the formation of “F-actin core” of invadopodia. Dynamin2 may also be involved in trafficking of MT1-MMP protease to the invadopodia to degrade extracellular matrix.

**Reference**

Correspondence to
Assistant Professor Tetsuya Takeda, Ph.D.
Department of Neuroscience, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Shikata-cho 2-5-1, Kita-ku, Okayama 700-8558, Japan
e-mail : ttakeda@okayama-u.ac.jp

Further information
Okayama University
1-1-1 Tsushima-naka, Kita-ku, Okayama 700-8530, Japan
Public Relations and Information Strategy
E-mail: www-adm@adm.okayama-u.ac.jp
Website: http://www.okayama-u.ac.jp/index_e.html
Okayama Univ. e-Bulletin: http://www.okayama-u.ac.jp/user/kouhou/ebulletin/
About Okayama University (You Tube):
https://www.youtube.com/watch?v=iDL1coqPRYI
Okayama University Image Movie (You Tube):
https://www.youtube.com/watch?v=WnbJVk2eiA
https://www.youtube.com/watch?v=KU3hOIX5kk

Okayama University Medical Research Updates (OU-MRU)
Vol.1 : Innovative non-invasive 'liquid biopsy' method to capture circulating tumor cells from blood samples for genetic testing
Vol.2 : Ensuring a cool recovery from cardiac arrest
Vol.3 : Organ regeneration research leaps forward
Vol.4 : Cardiac mechanosensitive integrator
Vol.5 : Cell injections get to the heart of congenital defects
Vol.6 : Fourth key molecule identified in bone development
Vol.7 : Anticancer virus solution provides an alternative to surgery
Vol.8 : Light-responsive dye stimulates sight in genetically blind patients
Vol.9 : Diabetes drug helps towards immunity against cancer
Vol.10 : Enzyme-inhibitors treat drug-resistant epilepsy
Vol.11 : Compound-protein combination shows promise for arthritis treatment
Vol.12 : Molecular features of the circadian clock system in fruit flies
Vol.13 : Peptide directs artificial tissue growth
Vol.14 : Simplified boron compound may treat brain tumours
Vol.15 : Metamaterial absorbers for infrared inspection technologies
Vol.16 : Epigenetics research traces how crickets restore lost limbs
Vol.17 : Cell research shows pathway for suppressing hepatitis B virus

© OKAYAMA University
Vol.18 : Therapeutic protein targets liver disease
Vol.19 : Study links signalling protein to osteoarthritis
Vol.20 : Lack of enzyme promotes fatty liver disease in thin patients
Vol.21 : Combined gene transduction and light therapy targets gastric cancer
Vol.22 : Medical supportive device for hemodialysis catheter puncture
Vol.23 : Development of low cost oral inactivated vaccines for dysentery
Vol.24 : Sticky molecules to tackle obesity and diabetes
Vol.25 : Self-administered aroma foot massage may reduce symptoms of anxiety
Vol.26 : Protein for preventing heart failure
Vol.27 : Keeping cells in shape to fight sepsis
Vol.28 : Viral-based therapy for bone cancer
Vol.29 : Photoreactive compound allows protein synthesis control with light
Vol.30 : Cancer stem cells’ role in tumor growth revealed
Vol.31 : Prevention of RNA virus replication

About Okayama University

Okayama University is one of the largest comprehensive universities in Japan with roots going back to the Medical Training Place sponsored by the Lord of Okayama and established in 1870. Now with 1,300 faculty and 14,000 students, the University offers courses in specialties ranging from medicine and pharmacy to humanities and physical sciences. Okayama University is located in the heart of Japan approximately 3 hours west of Tokyo by Shinkansen.